VRX/AGN addendum: If this deal were to be consummated, VRX would have to divest the US rights to Dysport because it’s the main competitor to Botox. This in itself isn’t a big deal, however, since Dysport is an inferior product (IMO) and a very distant #2.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”